Veraxa Biotech AG
VRXAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVeraxa Biotech AG operates in the Biotechnology space. VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. With a market capitalization of $226.3M, it sits in micro-cap territory. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Market Cap
$226.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.58
EPS (Fwd)
—
ROE
-871.4%
ROA
-50.0%
Cash
—
Total Debt
—
Free CF
$15.8M
52W Change
-83.1%
Annual Financials
Cash vs Debt
Where VRXA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VRXA finished 83.37% below its 150-day moving average ($8.30) and 84.44% below its 200-day moving average ($8.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VRXA overbought or oversold?
At the September 3, 2026 close, VRXA's RSI(14) was 22.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Free cash flow comes in at $15.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -871.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
As with any equity investment, VRXA carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VRXA.